• No results found

HER-2-positive breast cancer

Impressive Objective Response to Nab Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER 2 Positive Breast Cancer Patient

Impressive Objective Response to Nab Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER 2 Positive Breast Cancer Patient

... targeting HER-2 pathway plus chemotherapy has repre- sented a major progress in the management of patients with breast ...metastatic HER-2 positive ductal infiltrating ...

8

An In-Vivo Investigation of the Cardio-Protective Potential of Aspirin, β-oestradiol and Calcipotriol for Trastuzumab Treatment of Her-2 Positive Breast Cancer

An In-Vivo Investigation of the Cardio-Protective Potential of Aspirin, β-oestradiol and Calcipotriol for Trastuzumab Treatment of Her-2 Positive Breast Cancer

... of breast cancers that overexpress human epidermal growth factor receptor type 2 (Her-2) are aggressive and more difficult to treat with conventional chemotherapy than their oestrogen receptor ...

17

Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway

Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway

... on HER-2-positive breast cancer cells, but could not affect the anti-growth effect of aspirin in HER-2 negative breast cancer ...alone-treated ...

15

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer

... The advantages of TCH were demonstrated by comparing four chemotherapy regimens. For the remaining three groups, which did not receive trastuzumab, we concluded that the short-term efficacy of the XEC-XT group and the ...

9

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2

... in HER-2 positive breast cancer cells is closely related to overexpression of both epidermal growth factor receptor (EGFR) and human epidermal recep- tor ...on HER-2 ...

11

Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis

Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis

... The current analysis also found that application of lapa- tinib alone or in combination with trastuzumab resulted in more toxic side effects including diarrhea, skin rash, and liver function impairment, suggesting ...

12

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab

<p>A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab</p>

... in HER-2-positive advanced breast ...in breast cancer. 19 HER-2 overexpression in ductal carcinoma was signi fi - cantly associated with higher FOXP3+ TILs, and ...

9

HER 2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy

HER 2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy

... with HER-2 overexpression and TN BCs are at increased risk of developing LR following BCS ...present. Positive margins were reported to be significantly associated with large tumor size, young age, ...

9

Evidence Based Medicine, in Precision Oncology

Evidence Based Medicine, in Precision Oncology

... metastatic breast cancer, as well as disease-free and overall survival in patients with localized invasive breast ...said, Her 2 posi- tive breast cancer response to ...

17

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer

... with Her-2- positive breast cancer with no brain metastases (cohort 1) and with at least a single brain metastases ≥1 cm (cohort 2) as confirmed by ...metastatic breast ...

10

Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells

Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells

... (HER-2)-positive breast cancer tends to be aggressive, highly metastatic, and drug resistant and spreads ...inhibits HER-2 expression. This study compared the HER- ...

16

Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels

Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels

... inherent positive charge, cati- onic liposomes have a high affinity for most neg- atively charged cell ...prostate cancer xenografts (40) or gliomas in nude mice (41); an anti-TGF- ␣ AS oligonucleotide to ...

12

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

... staining, 2 denotes 1%–10% nuclei staining, 3 denotes 11%–33% nuclei stain- ing, 4 denotes 34%–66% nuclei staining, and 5 denotes 67%–100% nuclei ...staining, 2 denotes moderate staining, and 3 denotes ...

11

2. STUDY OF METASTATIC CANCER OF BREAST WITH SPECIAL REFERENCE TO BREAST CANCER SUBTYPES

2. STUDY OF METASTATIC CANCER OF BREAST WITH SPECIAL REFERENCE TO BREAST CANCER SUBTYPES

... Background: Breast cancer is a major medical problem with significant public health and societal ramifications and is a leading cause of cancer death in ...of breast cancer (luminal A, ...

9

Tumor escape and progression of HER 2/neu negative breast cancer under immune pressure

Tumor escape and progression of HER 2/neu negative breast cancer under immune pressure

... with HER-2/neu negative tumors compared to those with HER-2/neu positive tumors suggests the presence of high affinity T cells in the ...with HER-2/neu- tumors was asso- ...

5

A correlation study of the expression of HA-CD44st and HER-2 in breast cancer

A correlation study of the expression of HA-CD44st and HER-2 in breast cancer

... the positive expression rates of CD44st and HER-2 mRNA or protein in breast cancer ...and HER-2 were ...and HER-2 mRNA was also ...

12

The Effect of Neoadjuvant Chemotherapy on ER, PR and HER 2 Expression in Breast Cancer

The Effect of Neoadjuvant Chemotherapy on ER, PR and HER 2 Expression in Breast Cancer

... and HER-2 ex- pression in tumor tissue before and after neoadjuvant chemotherapy (NAC) in locally advanced breast cancer patient, to discuss whether there is influence for NACon ER, PR, ...

13

Association between Overexpression of Her 2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco

Association between Overexpression of Her 2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco

... of Her-2 in large tumors has been demonstrated in other studies [27,28] while in some studies this association has not been found ...a positive HER-2 status as low-grade tumors ...

6

Quantification of HER family receptors in breast cancer

Quantification of HER family receptors in breast cancer

... total HER-2 expression results are grouped as HERmark negative, HERmark equivocal, and HERmark ...a positive HERmark test is based on the comparison with HER2 tests performed in 1,090 breast ...

12

Negative genic switch of HER 2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2 positive breast cancer

Negative genic switch of HER 2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2 positive breast cancer

... by breast tissue micro- array (TMA) and matched node TMA that biomarkers’ status of metastatic nodal lesions could be a more accur- ate measurement for guiding adjuvant ...

5

Show all 10000 documents...

Related subjects